Sign In
3 Dec 2013 09:21
For immediate release | 3 December 2013 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR dealing: Share Incentive Plan
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of innovative protein research tools to help life scientists discover more, announces that following completion of three years of continued employment since the award of Free Shares on 2 December 2010 and Matching Shares on 3 December 2010 under the Share Incentive Plan, the risk of forfeiture attached to these shares has now been removed, resulting in an increase in the beneficial holding of each Director and PDMR as follows:
Free Shares now transferred to beneficial ownership | Matching Shares now transferred to beneficial ownership* | Total subsequent beneficial holding | Percentage of share capital | |
Executive Directors: | ||||
Jonathan Milner | 869 | 385 | 26,496,434 | 13.26% |
Jim Warwick | 869 | 385 | 2,943,884 | 1.47% |
Jeff Iliffe | 869 | 385 | 275,734 | 0.14% |
PDMRs: | ||||
Mark Bushfield | 869 | 34 | 7,377 | 0.01% |
Jane Cooke | 869 | 1 | 12,064 | 0.01% |
Philippe Cotrel | 869 | 34 | 11,093 | 0.01% |
Danielle Miller | 869 | 385 | 188,194 | 0.09% |
Ed Ralph | 869 | 386 | 360,244 | 0.18% |
\* The number of matching shares is determined by the individual's election to purchase shares within the Share Incentive Plan limits. Any contribution which is unable to purchase a whole ordinary share at market value on the date of award is rolled forward for future share awards.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Andy Crossley - Corporate Broking
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 127,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com
Follow the stocks
